This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clozapine and raised prolactin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • classic antipsychotic drugs can lead to marked increases in prolactin (probably via the blocking of dopamine receptors) - a study of schizophrenia patients on neuroleptic medication revealed a prevalence of galactorrhoea of 19% (1)
  • hyperprolactinaemia has also been reported with the use of atypical antipsychotics but the prevalence rates are unclear
  • clozapine may differ from other antipsychotics - the observed increases in prolactin have been lower and no amenorrhoea, galactorrhoea or inhibition of ejaculation have been reported (2); also patients, who have developed hyperprolactinaemia on conventional antipsychotics, have been treated subsequently with clozapine without a recurrence of hyperprolactinaemia (3)

Reference:

  1. Windgassen K, Wesselmann U, Schulze Monking H (1996). Galactorrhoea and hyperprolactinaemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology, 33, 142-6.
  2. Marken PA, Haykal RF, Fisher JN (1992). Management of psychotropic-induced hyperprolactinaemia. Clin Pharm, 11, 851-6.
  3. Bunker MT et al (1997). Attenuation of antipsychotic-induced hyperprolactinaemia with clozapine. J Child Adolesc Psychopharmacol, 7, 65-69.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.